Brief: Basilea Reports Acquisition Of Rights For Oncology Asset BAL0891 By Sillajen; Updates Financial Guidance

Basilea Pharmaceutica AG, Allschwil

20/09/2022 06:19

Sept 20 (Reuters) - Basilea Pharmaceutica Ag  BSLN.S :
    * BASILEA ANNOUNCES ACQUISITION OF RIGHTS FOR ONCOLOGY ASSET
BAL0891 BY SILLAJEN AND UPDATES FINANCIAL GUIDANCE
    * FULL-YEAR 2022 REVENUE GUIDANCE INCREASED, RESULTING IN
IMPROVED
EXPECTED OPERATING RESULT AND OPERATING CASH FLOW
    * EXPECTS HIGHER TOTAL REVENUES OF CHF 116 TO 122 MILLION
FOR FY
2022
    * SEES FY 2022 IMPROVED CASH FLOW FROM OPERATING ACTIVITIES
OF CHF
0 TO -5 MILLION
    * BASILEA WILL RECEIVE UPFRONT AND NEAR-TERM MILESTONE
PAYMENTS OF
USD 14 MILLION

Source text for Eikon:  ID:nGNX5WHzV 
Further company coverage:  BSLN.S 

 ((Reuters.Briefs@thomsonreuters.com;))